Patent · US Active

Antagonist antibodies against GDF-8

US7888486B2 · kind B2 · utility

63Cited by
17References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 14, 2006
Grant dateFeb 15, 2011
Priority date
Expiry dateAug 14, 2026

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.